| SCHEDULE OF INCOME TAXES |
SCHEDULE
OF INCOME TAXES
| |
|
Year
Ended
|
|
|
Year
Ended
|
|
| |
|
December
31, 2023 |
|
|
December
31, 2022 |
|
| |
|
£ |
|
|
£ |
|
| Current tax |
|
|
|
|
|
|
|
|
| Corporation
tax credit |
|
|
1,088,729 |
|
|
|
1,720,000 |
|
| Total current tax credit |
|
|
1,088,729 |
|
|
|
1,720,000 |
|
| |
|
|
|
|
|
|
|
|
| Reconciliation of loss before
tax to the tax credit for the year |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| Loss on ordinary activities multiplied by the
standard rate of tax of 23.5% (2022: 19%) |
|
|
1,643,985 |
|
|
|
576,384 |
|
| |
|
|
|
|
|
|
|
|
| Adjustments in respect of prior years |
|
|
45,136 |
|
|
|
154,422 |
|
| Non-deductible expenses |
|
|
(1,497,764 |
) |
|
|
(1,834,581 |
) |
| Super deductions |
|
|
- |
|
|
|
13,178 |
|
| Change in deferred tax asset |
|
|
- |
|
|
|
(186,879 |
) |
Change in valuation allowance |
|
|
357,897 |
|
|
|
(671,566
|
) |
| Foreign rate differential |
|
|
(29,318 |
) |
|
|
- |
|
| Other |
|
|
(233,096 |
) |
|
|
- |
|
| Additional allowance in respect of enhanced
R&D relief |
|
|
- |
|
|
|
4,198,115 |
|
| Surrender of tax losses for R&D tax credit
refund |
|
|
- |
|
|
|
(2,109,111 |
) |
| Adjustments relating to GAAP |
|
|
(241,704 |
) |
|
|
14,460 |
|
| R&D tax credits
generated |
|
|
1,043,593 |
|
|
|
1,565,578 |
|
| Current
tax credit |
|
|
1,088,729 |
|
|
|
1,720,000 |
|
|
| SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS |
Significant
components of the Company’s deferred tax assets as of December 31, 2023 and 2022 are summarized below.
SCHEDULE
OF COMPONENTS OF DEFERRED TAX ASSETS
| |
|
2023 |
|
|
2022 |
|
| Deferred tax assets: |
|
|
|
|
|
|
|
|
| Net operation losses |
|
£ |
4,357,668 |
|
|
£ |
4,433,305 |
|
| Fixed
asset |
|
|
79,338 |
|
|
|
71,426 |
|
| Other |
|
|
17,946 |
|
|
|
308,118 |
|
| Total
deferred tax assets |
|
|
4,454,952 |
|
|
|
4,812,849 |
|
| |
|
|
|
|
|
|
|
|
| Valuation
allowance |
|
|
(4,454,952 |
) |
|
|
(4,812,849 |
) |
| |
|
|
|
|
|
|
|
|
| Net
deferred tax asset, net of valuation allowance |
|
£ |
– |
|
|
£ |
– |
|
|